679 studies on GLP-1R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This study provides compelling real-world evidence that GLP-1 Receptor Agonist therapy offers substantial cardiorenal protection in Type 1 Diabetes patients, mirroring benefits previously observed in T2D. These findin…
This study addresses a crucial gap in managing obesity post-GLP-1 agonist therapy, which has significant implications for patient care and public health. If gradual withdrawal proves superior, it could establish a new…
The development of GZR18 represents a significant step towards addressing the unmet need for more convenient and effective long-term weight management solutions. The potential for a less frequent dosing regimen (every…
Obesity-related HFpEF is a major public health challenge with few targeted treatments, making the potential of Tirzepatide highly significant. If this study successfully identifies the mechanisms by which Tirzepatide …
This study highlights the critical importance of timing when discontinuing GLP-1RA/tirzepatide before pregnancy to mitigate gestational diabetes risk. While longer discontinuation periods appear safe, abrupt cessation…
This case report highlights a critical potential adverse effect of GLP-1 RAs on mood and behavior, particularly in vulnerable populations such as those with pre-existing Major Depressive Disorder. Given that GLP-1 rec…
This trial is crucial because it seeks to provide a much-needed treatment option for obesity in individuals with Type 1 Diabetes, a population with limited pharmacological interventions. A successful outcome could sig…
This real-world data underscores the substantial weight-loss benefits of GLP-1 RAs, particularly tirzepatide, in patients with rheumatic and musculoskeletal diseases, a population often challenged by weight management…
This review underscores the critical role of pharmacotherapy in modern obesity management, moving beyond traditional lifestyle interventions alone. The significant weight loss and cardiovascular benefits demonstrated …
The review highlights that GLP-1 RAs are highly effective for weight management and glycemic control, offering significant benefits for women with conditions like polycystic ovary syndrome (PCOS) or those at elevated …
The successful demonstration of bioequivalence means that this new Liraglutide injection can be considered therapeutically interchangeable with Victoza®. This is a significant step towards increasing patient access to…
This study is significant because it addresses a critical unmet need for effective and manageable weight loss interventions in a highly complex and often overlooked patient population. The successful completion of the…
The persistent cognitive dysfunction in Major Depressive Disorder (MDD) represents a significant burden for patients, often not adequately addressed by standard antidepressants. Semaglutide, a GLP-1 receptor agonist (…
This study is significant because it explores a novel application of GLP-1 receptor agonists beyond their established roles in diabetes and obesity, potentially positioning them as tools for proactive health optimizat…
This study is crucial for advancing personalized medicine in Type 2 Diabetes management. By comparing Semaglutide (a GLP-1 receptor agonist that enhances insulin secretion and reduces appetite) and Dapagliflozin (an S…
This research is significant because it investigates a potential new benefit of tirzepatide beyond weight management and metabolic improvement: reducing breast cancer risk. Given the strong link between obesity and br…
Understanding how GLP-1RAs and GIP/GLP-1-dual agonists affect ocular blood flow and retinal health is critically important given their widespread use in diabetes management. If these medications demonstrate a benefici…
This study provides important reassurance regarding the cardiovascular safety profile of tirzepatide in a high-risk population. Given tirzepatide's superior efficacy in glycemic control and weight reduction, demonstra…
If liraglutide proves effective in improving lung function, it would represent a significant pleiotropic benefit beyond its established role in glucose control and weight management for Type 2 Diabetes Mellitus patien…
This study is critically important because it addresses a significant unmet medical need for effective treatments for cognitive dysfunction in individuals with type 2 diabetes, a population at high risk for dementia. …
This finding is significant because it confirms that liraglutide can reach the central nervous system (CNS), providing a physiological basis for its observed central effects on appetite regulation, glucose homeostasis…
Obstructive sleep apnoea significantly impacts quality of life and carries substantial health risks, particularly in obese populations. Liraglutide, a GLP-1 analogue, is already approved for weight management and type…
This multicentre, non-interventional study provides invaluable real-world evidence on Liraglutide (Saxenda®) safety and effectiveness, which is critical for understanding its performance outside of controlled clinical…
This trial design is significant because chronic heart failure and type 2 diabetes represent a substantial global health burden, and understanding how GLP-1 (glucagon-like peptide-1) agonists impact cardiac function c…
This study highlights the potential for IDegLira to significantly improve the quality of life for very old patients with Type 2 Diabetes by streamlining their treatment. Simplifying medication regimens can enhance adh…
This Phase 3 trial is a critical step in evaluating CagriSema as a potentially more potent treatment for obesity and type 2 diabetes than current GLP-1 monotherapies. The large enrollment of 2500 participants and exte…
The potential findings from this study could significantly advance our understanding of Semaglutide's role in the long-term management of Type 2 Diabetes, particularly concerning the critical challenge of preventing w…
This research is crucial as it expands the understanding of GLP-1 RA efficacy beyond weight-centric applications, particularly for a patient population where weight loss might not be a primary goal or even desirable. …
This study provides crucial real-world evidence supporting the sustained renal benefits of oral semaglutide when patients transition from injectable GLP-1RAs. The convenience of an oral formulation could significantly…
This review provides a critical safety alert for clinicians prescribing semaglutide, emphasizing the need for increased vigilance regarding ocular symptoms. The findings suggest that patients on semaglutide should be …
This study provides reassuring short-term data regarding tirzepatide and calcitonin levels, suggesting that while a slight increase may occur, it generally remains within a safe range for adults with obesity. This fin…
A successful semaglutide nasal spray could offer a more convenient and potentially less invasive administration route for patients managing overweight or obesity. This novel delivery method could significantly improve…
Reducing NETosis could represent a novel therapeutic strategy for managing inflammation and progression in diabetic kidney disease and immune-mediated kidney diseases. Identifying specific drug classes like SGLT2 inhi…
This research is crucial for understanding the precise behavioral mechanisms through which GLP-1 receptor agonists promote weight loss, moving beyond self-reported data to direct observation. The identification of spe…
This study is crucial for understanding how Semaglutide performs in a diverse patient population under typical healthcare conditions, rather than idealized trial environments. Real-world evidence complements tradition…
This study provides a robust, scientifically-driven methodology for developing complex oral peptide formulations like semaglutide, potentially leading to more effective and patient-friendly treatment options. The enha…
This real-world study provides crucial insights into the practical application and effectiveness of semaglutide in a challenging patient population with Cardiovascular-Kidney-Metabolic Syndrome (CKM). The findings und…
This study provides compelling direct evidence that GLP-1 RAs acutely enhance the contractility of human heart muscle, independent of their systemic metabolic effects. This direct positive inotropic effect could be a …
The study demonstrated significant reductions in alcohol consumption and body weight in the semaglutide group compared to placebo. > Patients treated with semaglutide experienced a 43% reduction in weekly alcohol inta…
This study provides compelling evidence that Semaglutide offers significant cardiovascular protection beyond its established benefits for weight loss and diabetes management. This establishes Semaglutide as a crucial …
The review identified that GLP-1 RAs exert effects far beyond simple caloric restriction, significantly impacting neural circuits involved in reward processing and impulse control. They found that these agents can mod…